IPP Bureau
FDA greenlights Biocon’s Liraglutide for chronic weight management
By IPP Bureau - February 25, 2026
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Boehringer Ingelheim India appoints Meenal Gauri as Managing Director
By IPP Bureau - February 25, 2026
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
India shifts focus from 'Pharmacy of the World' to 'Global Innovation Hub', says Health Minister Nadda
By IPP Bureau - February 24, 2026
Nadda underlined that India’s policy framework is aligned with this transformation
iRegene doses first US Parkinson’s patient, launches landmark MSA trial in China
By IPP Bureau - February 24, 2026
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation
By IPP Bureau - February 24, 2026
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
By IPP Bureau - February 24, 2026
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Colgate joins hands with Haryana to bring oral health education to 5.7 million school children
By IPP Bureau - February 24, 2026
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
By IPP Bureau - February 24, 2026
Under the deal, Quiver will receive an undisclosed advance payment and research support
AbbVie to invest $380 million in new North Chicago manufacturing facilities
By IPP Bureau - February 24, 2026
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Bayer introduces chemo-free treatment option for advanced prostate cancer in India
By IPP Bureau - February 24, 2026
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
By IPP Bureau - February 24, 2026
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
By IPP Bureau - February 24, 2026
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
biomodal expands multiomic reach with Element Biosciences pact
By IPP Bureau - February 24, 2026
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Sai Life Sciences to hire 700+ professionals to support expansion
By IPP Bureau - February 24, 2026
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
By IPP Bureau - February 24, 2026
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
